Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.71 |
| ▸ | MAPT | P10636 | 10/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14864068 | 0.89 | MEN1 (0.67) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL9727540 | 0.86 | NPSR1 (0.68) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL6132364 | 0.84 | GAA (0.69) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL13100984 | 0.84 | KMT2A (0.55) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL4978561 | 0.83 | MEN1 (0.59) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL6901859 | 0.83 | KMT2A (0.50) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL4753923 | 0.83 | MAPT (0.62) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL13101500 | 0.82 | MAPT (0.62) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL1871457 | 0.82 | ALDH1A1 (0.70) | ALDH1A1KMT2A | |
| SCHEMBL975238 | 0.82 | NPSR1 (0.60) | ALDH1A1MAPTSMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521440-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BEONE MEDICINES I GMBH (CH) | 2026-01-13 | — | — | US | disclosed |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-26 | — | — | US | disclosed |
| US-20240366769-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| WO-2024102970-A1 | COMPOUNDS FOR MODULATING SYK ACTIVITY AND E3 UBIQUITIN LIGASE ACTIVITY | Kronos Bio, Inc. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023125908-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| CN-114901659-A | Fused pyrimidinone compounds as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-24 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20100190789-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190789-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-29 | — | — | US | disclosed |
| US-20100184776-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-22 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| EP-2041132-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008148851-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148868-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008003766-A2 | 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366769-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | ALDH1A1 4351/4885MAPT 3793/4885SMN1; SMN2 3792/4885 |
| US-20100184776-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | NR5A2, DLAT, NR2C2 | ALDH1A1 1529/4885MAPT 983/4885SMN1; SMN2 3601/4885 |
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 2446/4885MAPT 3409/4885SMN1; SMN2 3707/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 2446/4885MAPT 3409/4885SMN1; SMN2 3707/4885 |
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | ALDH1A1 398/4885MAPT 3181/4885SMN1; SMN2 158/4885 |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | ALDH1A1 4351/4885MAPT 3793/4885SMN1; SMN2 3792/4885 |
| US-20100190789-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | NR2C2, NR5A2, DGAT1 | ALDH1A1 1064/4885MAPT 1787/4885SMN1; SMN2 2910/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | ALDH1A1 293/4885MAPT 4431/4885SMN1; SMN2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.